What patients need to know about Onglyza.
Studies linking Onglyza to patient side effects.
FDA heart failure warnings.
Pending Onglyza side effects lawsuits.
TYPE 2 DIABETES DRUG
Onglyza is a new DPP-4 inhibitor medication for type 2 diabetes that was prescribed more than 1.7 million times in the United States last year.
STUDIES & FDA WARNINGS
A recent Brigham and Women's/Harvard study found those taking Onglyza more likely to be hospitalized for heart failure. Despite FDA recommendations, the manufacturer of the drug has failed to warn patients of the heart failure risks.
HEART FAILURE LAWSUITS
Lawyers have begun filing lawsuits on behalf of those patients who suffered heart problems after taking Onglyza. Contact us to speak with a lawyer today at no cost.